scholarly journals The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review

2010 ◽  
Vol 12 (4) ◽  
pp. 500-508 ◽  
Author(s):  
Ryan W. Frieben ◽  
Hao-Cheng Lin ◽  
Peter P. Hinh ◽  
Francesco Berardinelli ◽  
Steven E. Canfield ◽  
...  
Keyword(s):  
Systematic Review ◽  
Benign Prostatic Hyperplasia ◽  
Minimally Invasive ◽  
Sexual Function ◽  
Prostatic Hyperplasia ◽  
Symptomatic Benign Prostatic Hyperplasia ◽  
Male Sexual Function ◽  
The Impact

scholarly journals 525 Minimally Invasive Surgical Treatment of Benign Prostatic Hyperplasia: A Systematic Review

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
A Ting ◽  
N Shanmugathas ◽  
C Khoo ◽  
R Dasgupta ◽  
T El-Husseiny ◽  
...  
Keyword(s):  
Systematic Review ◽  
Benign Prostatic Hyperplasia ◽  
Minimally Invasive ◽  
Sexual Function ◽  
Functional Change ◽  
Prostatic Hyperplasia ◽  
Urinary Continence ◽  
Minimally Invasive Surgical ◽  
Technical Failures

Abstract Introduction Minimally invasive surgical treatments (MISTs) of benign prostatic hyperplasia (BPH) have evolved to offer men daycase care with preservation of urinary continence and sexual function. This systematic review evaluates trends in minimally invasive BPH surgery over the last decade Method Systematic review (PRISMA) of Embase/MEDLINE databases (2010-2020). MISTs included Rezum, Urolift, Prostatic Artery Embolisation (PAE), Temporary Implantable Nitinol Device (TIND), Intraprostatic Injection, Transurethral Microwave Therapy (TUMT) and Transurethral Needle Ablation (TUNA). Primary outcome: urinary functional change (International Prostate Symptom Score (IPSS)/maximum flow (Qmax)). Secondary outcomes: sexual functional change (International Index of Erectile Function-5 (IIEF-5)), technical failures and complications. Results 74 studies were included (total: 8,917 patients). Primary: all interventions offered improvement in IPSS and Qmax (intervention (no. studies): range IPSS change, range Qmax change, range months follow-up; Rezum (4): -46.7% to -62.7%, +17.6% to + 55.6%, 6-48; Urolift (11): -35.2% to -64.2%, +16.7% to + 89.6%, 1-60; PAE (36): -36.8% to -85.2%, +17.4% to + 155.2%, 3-38; TIND (2): -36.8% to -59.6%, +32.9% to + 95.9%, 12-36; Intraprostatic Injection (14): -24.3% to -62%, +8.7% to + 98.4%, 3-24; TUMT (4): -56.1% to -58.7%, +12.9% to + 60.2%, 6-60; TUNA (3): -17.6% to -63.2%, +3.9% to + 39%, 1-120). Secondary: 33 studies of all interventions bar TIND and TUMT reported IIEF-5 change; sexual function was largely preserved. Technical failures and Clavien-Dindo ≥3 complications were rare. Conclusions MISTs for BPH are efficacious and safe. Randomised comparisons with long-term urinary and sexual follow-up are needed to guide choice; until then, patients should be carefully counselled based on individual priorities and circumstances.

scholarly journals Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia

2018 ◽  
Vol 10 (11) ◽  
pp. 327-333 ◽  
Author(s):  
Jennifer Westwood ◽  
Robert Geraghty ◽  
Patrick Jones ◽  
Bhavan P. Rai ◽  
Bhaskar K. Somani
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Minimally Invasive ◽  
Sexual Function ◽  
Water Vapour ◽  
Thermal Energy ◽  
Prostatic Hyperplasia ◽  
Benign Prostatic Enlargement ◽  
Short Term ◽  
Safety And Efficacy ◽  
Prostatic Enlargement

Rezum is a minimally invasive transurethral water vapour therapy for benign prostatic enlargement which uses thermal energy for treatment. The short-term results show it to have good outcomes with a potential for outpatient-based treatment preserving sexual function. This review serves to provide an overview of the technique and evaluate its safety and efficacy.

Sign in / Sign up

Export Citation Format

Share Document